There was a strong correlation between the percentage change in MUFAs and PUFAs after one cycle of NACT and the percentage change in CD163, indicating that an increased bioavailability of MUFAs and PUFAs was associated with a sustained immune response of the tumour, although not a predictor of overall treatment response [16]. This evidence concerns the gene CD163 and neoplasm.